However, both peptides were effective, and the difference was not large
Research has examined its role in: 3-adrenergic receptor upregulation and adipose tissue sensitisation studies Lipolysis stimulation and plasma glycerol elevation in adipocyte models Lipogenesis inhibition and fat accumulation prevention in diet-induced obesity models Fat oxidation and energy expenditure pathway research Metabolic flexibility and substrate oxidation studies in obese murine models Cartilage regeneration and intra-articular joint biology in osteoarthritis models Safety pharmacology genotoxicity, bioavailability, and plasma kinetics profiling Comparative hGH fragment activity studies alongside AOD9401 and native hGH AOD9604 and Adipose Tissue Research In obese Zucker rats treated with oral AOD9604 at 500 g/kg body weight for 19 days, over 50% reduction in body weight gain was observed compared to controls, accompanied by significantly increased lipolytic activity in adipose tissue

True inconsistency (some days fasted, some days not) requires behavior change rather than timing change
The mouse research that established its mechanism and preclinical effects used subcutaneous injection at a fixed research dose (20 mg/kg, three times daily) a research-animal protocol, not a human administration guide
Why people explore AOD 9604/MOTS-C AOD 9604 drives lipolysis to break down existing fat stores
Appetite suppression is not the primary mechanism